Patrizia Ferroni

List of Publications by Year
in descending order

		87723	128067
174 papers	4,972 citations	38 h-index	60 g-index
175 all docs	175 docs citations	175 times ranked	7766 citing authors

#	Article	IF	Citations
1	Platelet activation in type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis, 2004, 2, 1282-1291.	1.9	380
2	Obesity and colorectal cancer: Role of adipokines in tumor initiation and progression. World Journal of Gastroenterology, 2014, 20, 5177.	1.4	157
3	Soluble RAGE in type 2 diabetes: Association with oxidative stress. Free Radical Biology and Medicine, 2007, 43, 511-518.	1.3	125
4	Inflammation, insulin resistance, and obesity. Current Atherosclerosis Reports, 2004, 6, 424-431.	2.0	120
5	Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments. Pharmacogenomics, 2012, 13, 595-613.	0.6	115
6	Association between Circulating Adiponectin and Interleukin-10 Levels in Android Obesity: Effects of Weight Loss. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5876-5879.	1.8	114
7	Breast Cancer Prognosis Using a Machine Learning Approach. Cancers, 2019, 11, 328.	1.7	101
8	Soluble P-selectin as a marker of in vivo platelet activation. Clinica Chimica Acta, 2009, 399, 88-91.	0.5	100
9	Endothelial dysfunction and oxidative stress in arterial hypertension. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 222-233.	1.1	96
10	Malignant Mesothelioma Effusions Are Infiltrated byâCD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Antiâ€"PD-L1 Antibody Avelumab. Journal of Thoracic Oncology, 2016, 11, 1993-2005.	0.5	96
11	CD40/CD40L system and vascular disease. Internal and Emergency Medicine, 2007, 2, 256-268.	1.0	88
12	Biomarkers of platelet activation in acute coronary syndromes. Thrombosis and Haemostasis, 2012, 108, 1109-1123.	1.8	81
13	Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. Journal of Investigative Medicine, 2003, 51, 295-300.	0.7	75
14	Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis. Current Medicinal Chemistry, 2007, 14, 2170-2180.	1.2	66
15	Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor Prognosis. Journal of the National Cancer Institute, 2014, 106, .	3.0	65
16	Ca 72-4 radioimmunoassay for the detection of the tag-72 carcinoma-associated antigen in serum of patients. Journal of Clinical Laboratory Analysis, 1989, 3, 360-369.	0.9	64
17	Platelet Activation, Inflammatory Mediators and Hypercholesterolemia. Current Vascular Pharmacology, 2003, 1, 157-169.	0.8	64
18	Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-10.	1.9	63

#	Article	IF	Citations
19	Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients. Medical Decision Making, 2017, 37, 234-242.	1.2	63
20	Soluble CD40 Ligand Plasma Levels in Lung Cancer. Clinical Cancer Research, 2004, 10, 610-614.	3.2	62
21	Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. International Journal of Cancer, 2006, 119, 955-960.	2.3	62
22	Hypercoagulability State in Patients with Chronic Obstructive Pulmonary Disease. Thrombosis and Haemostasis, 1994, 72, 343-346.	1.8	62
23	Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. International Journal of Cancer, 2015, 136, 1234-1240.	2.3	60
24	Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities. Antioxidants and Redox Signaling, 2012, 17, 1447-1485.	2.5	57
25	Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Research, 2009, 29, 3321-7.	0.5	56
26	Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. Oncologist, 2016, 21, 1041-1049.	1.9	49
27	Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology. Disease Markers, 2017, 2017, 1-7.	0.6	49
28	Oxidant Stress and Platelet Activation in Hypercholesterolemia. Antioxidants and Redox Signaling, 2004, 6, 747-756.	2.5	48
29	Novel High-Sensitive D-Dimer Determination Predicts Chemotherapy-Associated Venous Thromboembolism in Intermediate Risk Lung Cancer Patients. Clinical Lung Cancer, 2012, 13, 482-487.	1.1	48
30	Platinum-Based Compounds and Risk for Cardiovascular Toxicity in the Elderly: Role of the Antioxidants in Chemoprevention. Rejuvenation Research, 2011, 14, 293-308.	0.9	47
31	Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. In Vivo, 2007, 21, 147-61.	0.6	47
32	CA 72-4 Serum Marker–A New Tool in the Management of Carcinoma Patients. Cancer Investigation, 1995, 13, 227-238.	0.6	45
33	Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis, 1999, 147, 249-252.	0.4	44
34	Preanalytical Procedures for DNA Studies: The Experience of the Interinstitutional Multidisciplinary BioBank (BioBIM). Biopreservation and Biobanking, 2011, 9, 35-45.	0.5	44
35	Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Medical Oncology, 2014, 31, 166.	1.2	43
36	Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thrombosis and Haemostasis, 2003, 89, 177-184.	1.8	42

#	ARTICLE	IF	CITATIONS
37	Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs. Current Vascular Pharmacology, 2010, 8, 102-113.	0.8	41
38	Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Research, 2007, 27, 483-9.	0.5	41
39	Enhanced Interleukin-1Î² in Hypercholesterolemia. Circulation, 2003, 108, 1673-1675.	1.6	37
40	Prognostic value of soluble P-selectin levels in colorectal cancer. International Journal of Cancer, 2004, 111, 404-408.	2.3	37
41	Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics, 2014, 15, 2063-2082.	0.6	37
42	Prognostic Value of Vascular Endothelial Growth Factor Tumor Tissue Content of Colorectal Cancer. Oncology, 2005, 69, 145-153.	0.9	36
43	Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Research and Treatment, 2001, 68, 9-19.	1.1	35
44	Anoxia-Reoxygenation Enhances Platelet Thromboxane A$_2$ Production via Reactive Oxygen Speciesâ€"Generated NOX2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1766-1771.	1.1	35
45	Obesity-Driven Inflammation and Colorectal Cancer. Current Medicinal Chemistry, 2012, 19, 5837-5853.	1.2	35
46	Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. Journal of Investigative Medicine, 2003, 51, 295.	0.7	35
47	Genetics and genomics of ischemic tolerance: focus on cardiac and cerebral ischemic preconditioning. Pharmacogenomics, 2012, 13, 1741-1757.	0.6	34
48	Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers, 2019, 11, 95.	1.7	33
49	Towards the Interpretability of Machine Learning Predictions for Medical Applications Targeting Personalised Therapies: A Cancer Case Survey. International Journal of Molecular Sciences, 2021, 22, 4394.	1.8	33
50	Ca 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. International Journal of Cancer, 1990, 46, 445-451.	2.3	32
51	Is Soluble P-selectin Determination a More Reliable Marker of In Vivo Platelet Activation than CD62P Flow Cytometric Analysis?. Thrombosis and Haemostasis, 1999, 81, 472-473.	1.8	32
52	Serum sEâ€selectin levels and carcinoembryonic antigen mRNAâ€expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. Cancer, 2010, 116, 2913-2921.	2.0	32
53	Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. Endocrine-Related Cancer, 2016, 23, 783-796.	1.6	31
54	Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Research, 2007, 27, 3147-62.	0.5	31

#	Article	IF	Citations
55	Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thrombosis Research, 2009, 124, 403-408.	0.8	30
56	Low‑grade endotoxemia and clotting activation in the early phase of pneumonia. Respirology, 2016, 21, 1465-1471.	1.3	29
57	Prognostic Value of Carcinoembryonic Antigen and Vascular Endothelial Growth Factor Tumor Tissue Content in Colorectal Cancer. Oncology, 2006, 71, 176-184.	0.9	27
58	Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations. Journal of Pain Research, 2017, Volume 10, 2319-2329.	0.8	27
59	Redox Mechanisms in Migraine: Novel Therapeutics and Dietary Interventions. Antioxidants and Redox Signaling, 2018, 28, 1144-1183.	2.5	27
60	Angiogenesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Therapies. Current Vascular Pharmacology, 2012, 10, 479-493.	0.8	26
61	Impact of chemotherapy on activated protein C‑dependent thrombin generation—Association with VTE occurrence. International Journal of Cancer, 2013, 133, 1253-1258.	2.3	26
62	The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. OncoImmunology, 2016, 5, e1188243.	2.1	26
63	Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine. Current Medicinal Chemistry, 2019, 26, 6191-6206.	1.2	25
64	Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer. International Journal of Biological Markers, 2003, 18, 21-27.	0.7	25
65	Blood Leukotrienes in Headache: Correlation With Platelet Activity. Headache, 1991, 31, 409-414.	1.8	24
66	Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clinical Science, 2008, 114, 449-455.	1.8	24
67	Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clinical Biochemistry, 2010, 43, 666-670.	0.8	24
68	Oxidant stress as a major determinant of platelet activation in invasive breast cancer. International Journal of Cancer, 2017, 140, 696-704.	2.3	24
69	Correlation between tumor necrosis factor-alpha and d-dimer levels in non-small cell lung cancer patients. Lung Cancer, 2004, 44, 303-310.	0.9	23
70	Low-Density Lipoprotein-Lowering Medication and Platelet Function. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 346-354.	0.5	23
71	In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients. Clinica Chimica Acta, 2008, 388, 33-37.	0.5	23
72	Machine learning approach to predict medication overuse in migraine patients. Computational and Structural Biotechnology Journal, 2020, 18, 1487-1496.	1.9	23

#	Article	IF	Citations
73	Acid citrate dextrose (acd) formula a as a new anticoagulant in the measurement of in vitro platelet aggregation. Journal of Clinical Laboratory Analysis, 1995, 9, 138-140.	0.9	22
74	RFID as a New ICT Tool to Monitor Specimen Life Cycle and Quality Control in a Biobank. International Journal of Biological Markers, 2011, 26, 129-135.	0.7	22
75	Increased Risk of Chemotherapy-Associated Venous Thromboembolism in Elderly Patients with Cancer. Rejuvenation Research, 2013, 16, 224-231.	0.9	22
76	Is *SOD2* Ala16Val Polymorphism Associated with Migraine with Aura Phenotype?. Antioxidants and Redox Signaling, 2015, 22, 275-279.	2.5	22
77	The role of anti-CGRP antibodies in the pathophysiology of primary headaches. Neurological Sciences, 2017, 38, 31-35.	0.9	22
78	Determinants of homocysteine levels in colorectal and breast cancer patients. Anticancer Research, 2009, 29, 4131-8.	0.5	22
79	Involvement of GD3 in platelet activation. A novel association with Fcgamma receptor. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1583, 297-304.	1.2	21
80	Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications. Cardiovascular & Hematological Disorders Drug Targets, 2008, 8, 194-202.	0.2	21
81	TNFA Gene Promoter Polymorphisms and Susceptibility to Recurrent Pregnancy Loss in Italian Women. Reproductive Sciences, 2010, 17, 659-666.	1.1	21
82	Impact of Preanalytical Handling and Timing for Peripheral Blood Mononuclear Cells Isolation and RNA Studies: The Experience of the Interinstitutional Multidisciplinary BioBank (BioBIM). International Journal of Biological Markers, 2012, 27, 90-98.	0.7	21
83	Increased Soluble P-Selectin Levels in Hepatitis C Virus-Related Chronic Hepatitis. Journal of Investigative Medicine, 2001, 49, 407-412.	0.7	20
84	An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thrombosis and Haemostasis, 2011, 105, 931-932.	1.8	20
85	Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). Medical Oncology, 2013, 30, 743.	1.2	20
86	Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica, 2014, 99, 1638-1644.	1.7	20
87	SPRECware: Software Tools for Standard PREanalytical Code (SPREC) Labeling – Effective Exchange and Search of Stored Biospecimens. International Journal of Biological Markers, 2012, 27, 272-279.	0.7	19
88	Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. International Journal of Colorectal Disease, 2012, 27, 1561-1567.	1.0	18
89	Ganglioside Content of Human Platelets – Differences in Resting and Activated Platelets. Thrombosis and Haemostasis, 1997, 77, 548-554.	1.8	18
90	Birt-Hogg-Dubé (BHD) syndrome: report of two novel germline mutations in the folliculin (FLCN) gene. European Journal of Dermatology, 2008, 18, 382-6.	0.3	18

#	Article	IF	Citations
91	VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clinical Biochemistry, 2010, 43, 1090-1095.	0.8	17
92	Effects of mud-pack treatment on plasma cytokine and soluble adhesion molecule levels in healthy volunteers. Clinica Chimica Acta, 2001, 314, 209-214.	0.5	16
93	Association between Serum Carcinoembryonic Antigen and Endothelial Cell Adhesion Molecules in Colorectal Cancer. Oncology, 2003, 65, 132-138.	0.9	16
94	TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. Annals of Oncology, 2013, 24, 2571-2575.	0.6	16
95	Look beyond Catechol-O-Methyltransferase genotype for cathecolamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study. Journal of Headache and Pain, 2015, 16, 520.	2.5	16
96	Prognostic Significance of Neutrophil–to–lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer. Anticancer Research, 2018, 38, 4705-4712.	0.5	16
97	Determinants of platelet activation in hypertensives with microalbuminuria. Free Radical Biology and Medicine, 2009, 46, 922-927.	1.3	15
98	Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer. Clinica Chimica Acta, 2011, 412, 450-454.	0.5	15
99	Functional impairment in video terminal operators is related to low-grade inflammation. International Archives of Occupational and Environmental Health, 2011, 84, 745-751.	1.1	15
100	Possible involvement of tumour cell membrane gangliosides in platelet-tumour cell interactions. European Journal of Cancer, 1995, 31, 79-84.	1.3	14
101	Tumor necrosis factor-alpha and myocardial function in patients with myotonic dystrophy type 1. Journal of the Neurological Sciences, 2002, 201, 59-64.	0.3	14
102	Increased plasminogen activator inhibitor-1 levels in android obesity: correlation with oxidative stress. Journal of Thrombosis and Haemostasis, 2005, 3, 1086-1087.	1.9	14
103	Establishment of a biorepository for migraine research: the experience of Interinstitutional Multidisciplinary BioBank (BioBIM). Neurological Sciences, 2013, 34, 1659-1663.	0.9	14
104	Prognostic value of glycated hemoglobin in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 9984.	1.4	14
105	CD40-CD40L interactions in platelet activation. Thrombosis and Haemostasis, 2005, 93, 1011-1012.	1.8	13
106	Clinical models and biochemical predictors of VTE in lung cancer. Cancer and Metastasis Reviews, 2014, 33, 771-789.	2.7	13
107	Progesterone Receptor Gene (PROGINS) Polymorphism Correlates with Late Onset of Migraine. DNA and Cell Biology, 2015, 34, 208-212.	0.9	13
108	VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. Thrombosis and Haemostasis, 2016, 115, 143-151.	1.8	13

#	Article	IF	Citations
109	Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. Cancer Biomarkers, 2016, 17, 335-345.	0.8	13
110	Impact of Statins on the Coagulation Status of Type 2 Diabetes Patients Evaluated by a Novel Thrombin-Generation Assay. Cardiovascular Drugs and Therapy, 2012, 26, 301-309.	1.3	12
111	Impact of *VEGF* gene polymorphisms in elderly cancer patients: clinical outcome and toxicity. Pharmacogenomics, 2015, 16, 61-78.	0.6	12
112	Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2017, 15, 3-16.	0.4	12
113	Microparticles in type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis, 2005, 3, 1166-1167.	1.9	11
114	Prognostic significance of interleukin-6 measurement in the diagnosis of acute myocardial infarction in emergency department. Clinica Chimica Acta, 2007, 381, 151-156.	0.5	11
115	Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease. European Journal of Internal Medicine, 2016, 33, 74-80.	1.0	11
116	Artificial intelligence for cancer-associated thrombosis risk assessment. Lancet Haematology,the, 2018, 5, e391.	2.2	11
117	Evaluation of the clinical utility of platelet aggregation studies in the long-term follow-up of patients with atherosclerotic vascular disease. Journal of Clinical Laboratory Analysis, 1992, 6, 257-263.	0.9	10
118	Effects of storage on in vitro platelet responses: Comparison of ACD and Na citrate anticoagulated samples. , 1996, 10, 134-139.		10
119	Association between migraine and *ACE* gene (insertion/deletion) polymorphism: the BioBIM study. Pharmacogenomics, 2014, 15, 147-155.	0.6	10
120	Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus. Current Vascular Pharmacology, 2013, 11, 338-351.	0.8	10
121	Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases. Journal of Clinical Medicine, 2021, 10, 87.	1.0	10
122	Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. American Journal of Obstetrics and Gynecology, 1994, 171, 1183-1191.	0.7	9
123	Proinflammatory cytokines and hemostatic system in patients with chronic obstructive pulmonary disease. Platelets, 1997, 8, 255-260.	1.1	9
124	Soluble P-Selectin and Proinflammatory Cytokines in Patients with Polygenic Type IIa Hypercholesterolemia. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 277-285.	0.5	9
125	Insulin resistance as a predictor of venous thromboembolism in breast cancer. Endocrine-Related Cancer, 2016, 23, L25-L28.	1.6	9
126	Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine. Neurological Sciences, 2019, 40, 1717-1724.	0.9	9

#	Article	IF	Citations
127	Gender Differences in Cancer-associated Venous Thromboembolism. Current Medicinal Chemistry, 2017, 24, 2589-2601.	1.2	9
128	Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management. Cardiovascular & Hematological Disorders Drug Targets, 2016, 15, 187-203.	0.2	9
129	Estimated Glomerular Filtration Rate Is an Easy Predictor of Venous Thromboembolism in Cancer Patients Undergoing Platinum€Based Chemotherapy. Oncologist, 2014, 19, 562-567.	1.9	8
130	Predictive value of HDL cholesterol for cancer€associated venous thromboembolism during chemotherapy. Journal of Thrombosis and Haemostasis, 2014, 12, 2049-2053.	1.9	8
131	Procoagulant imbalance in premenopausal women with chronic migraine. Neurology, 2017, 89, 1525-1527.	1.5	8
132	Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients€"a pilot study. Supportive Care in Cancer, 2012, 20, 2713-2720.	1.0	7
133	Impact of chemotherapy on venous thromboembolism: Comment to: Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica, 2013, 98, e153-e154.	1.7	7
134	Assay for the detection of anti-idiotypic antibodies to monoclonal antibody b72.3. Journal of Clinical Laboratory Analysis, 1990, 4, 465-473.	0.9	6
135	In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1991, 18, 395-401.	0.3	6
136	In Vivo Thrombin Generation and Platelet Hyperactivity in Patients with Chronic Obstructive Pulmonary Disease. Platelets, 1994, 5, 276-278.	1.1	6
137	In vivo platelet activation is associated with increased plasma levels of vascular endothelial growth factor. Journal of Thrombosis and Haemostasis, 2003, 1, 853-854.	1.9	6
138	Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer. World Journal of Gastroenterology, 2017, 23, 5187.	1.4	6
139	Effects of Isolated Limb Perfusion With Tumor Necrosis Factor-α on Circulating Levels of Proinflammatory Cytokines. Journal of Immunotherapy, 2001, 24, 354-362.	1.2	5
140	Predictive value of thrombopath determination in women with infertility and pregnancy complications. Clinica Chimica Acta, 2010, 411, 37-42.	0.5	5
141	A Reliable and Reproducible Technique for DNA Fingerprinting in Biorepositories: A Pilot Study from BioBIM. International Journal of Biological Markers, 2013, 28, 398-404.	0.7	5
142	Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care. Cancers, 2020, 12, 1167.	1.7	5
143	Effects on platelet function of combination etoposide and carboplatin chemotherapy in pediatric oncology patients. Platelets, 1998, 9, 309-314.	1.1	4
144	Aging: an important risk factor in chemotherapy-associated vascular diseases. Expert Review of Anticancer Therapy, 2013, 13, 899-901.	1.1	4

#	Article	IF	Citations
145	An importance of identification of double variant methylenetetrahydrofolate reductase gene C677T and A1298C in cis configuration for pharmacogenetic studies. Blood Coagulation and Fibrinolysis, 2013, 24, 784-786.	0.5	4
146	RISK: A Random Optimization Interactive System Based on Kernel Learning for Predicting Breast Cancer Disease Progression. Lecture Notes in Computer Science, 2017, , 189-196.	1.0	4
147	Genetic bases of the nutritional approach to migraine. Critical Reviews in Food Science and Nutrition, 2019, 59, 2308-2320.	5.4	4
148	Absolute neutrophil counts and fibrinogen levels as an aid in the early diagnosis of acute myocardial infarction. Acta Cardiologica, 2004, 59, 135-140.	0.3	4
149	A multiparametric index of platelet in vitro aggregation in cerebrovascular disease. Italian Journal of Neurological Sciences, 1987, 8, 561-566.	0.1	3
150	Platelet proaggregating activity of human colorectal tumour cell lines does not correlate with the degree of differentiation. European Journal of Cancer, 1993, 29, 1028-1033.	1.3	3
151	Circulating Transforming Growth Factor-β1 Levels in Asymptomatic Carotid Plaques. Stroke, 2005, 36, 525-526.	1.0	3
152	Protease nexin-1: a regulator of vascular disease?. Journal of Thrombosis and Haemostasis, 2006, 4, 320-321.	1.9	3
153	Precision medicine in the ageing world: The role of biospecimen sciences. International Journal of Biological Markers, 2019, 34, 3-5.	0.7	3
154	Diagnostic Procedures for Paraffin-Embedded Tissues Analysis in Pharmacogenomic Studies. Methods in Molecular Biology, 2014, 1175, 45-65.	0.4	3
155	A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. In Vivo, 2012, 26, 537-47.	0.6	3
156	Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1991, 18, 383-387.	0.3	2
157	POTENTIAL USEFULNESS OF ANTIPLATELET AGENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Thrombosis Research, 1996, 84, 279-284.	0.8	2
158	Rebuttal to Circulating IL-6 Levels in Chronic Obstructive Pulmonary Disease. Thrombosis and Haemostasis, 2001, 85, 373-373.	1.8	2
159	Factor Seven Activating Protease Activity Levels in Women With Recurrent Pregnancy Loss. Reproductive Sciences, 2012, 19, 317-321.	1.1	2
160	Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients. Thrombosis and Haemostasis, 2012, 108, 1243-1245.	1.8	2
161	Platelet Function: the Janus face of haemostasis in cirrhosis. Thrombosis Research, 2015, 135, 1224-1225.	0.8	2
162	Reply to: Lipoprotein (a) and chronic obstructive pulmonary disease. Atherosclerosis, 2001, 155, 525-526.	0.4	1

#	Article	IF	Citations
163	VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea. Annals of Oncology, 2011, 22, 1928-1929.	0.6	1
164	Research Highlights: Highlights from the latest articles in stroke pharmacogenomics. Pharmacogenomics, 2013, 14, 13-16.	0.6	1
165	DNA fingerprinting for sample authentication in biobanking: recent perspectives. Journal of Biorepository Science for Applied Medicine, 2015, , 35.	0.2	1
166	Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. Cancers, 2021, 13, 1556.	1.7	1
167	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. Current Medicinal Chemistry, 2021, 28, 3158-3172.	1.2	1
168	Functional impairment of activated protein C in breast cancer - relationship to survival outcomes. American Journal of Cancer Research, 2016, 6, 1450-7.	1.4	1
169	Importance of haplotype analysis in association studies considering VEGF promoter polymorphisms. Clinical Biochemistry, 2011, 44, 748.	0.8	0
170	Sample PREanalytical Code for labeling of biospecimens: an analysis of specimen labeling protocols. Journal of Biorepository Science for Applied Medicine, 2015, , 15.	0.2	0
171	VEGF and VTE Risk in Cancer Patients—Letter. Clinical Cancer Research, 2016, 22, 1295-1295.	3.2	0
172	Chemoprevention of Colonic Cancer Is There a Foreseeable Future?. , 2009, , 77-93.		0
173	Abstract 1403: Correlations between overall survival and patient regulatory T-cell levels at initiation of Folfiri therapy in colorectal cancer. , 2016, , .		0
174	Meet Our Section Editor. Current Medicinal Chemistry, 2019, 26, 361-361.	1.2	0